Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Leonard Bell sold 100 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $144.99, for a total value of $14,499.00. Following the completion of the sale, the director now owns 403,719 shares in the company, valued at $58,535,217.81. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Leonard Bell also recently made the following trade(s):

  • On Monday, January 9th, Leonard Bell sold 40,065 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $138.48, for a total value of $5,548,201.20.
  • On Friday, November 4th, Leonard Bell sold 37,317 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $140.38, for a total value of $5,238,560.46.
  • On Monday, October 31st, Leonard Bell sold 1,300 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $135.28, for a total value of $175,864.00.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.93 on Friday. The stock has a market cap of $30.66 billion, a price-to-earnings ratio of 83.49 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 12-month low of $109.12 and a 12-month high of $169.84. The company has a 50-day moving average price of $122.56 and a 200 day moving average price of $125.32.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. During the same quarter last year, the business earned $1.16 earnings per share. Alexion Pharmaceuticals’s revenue was up 19.9% compared to the same quarter last year. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $4.64 EPS for the current year.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this story can be accessed at http://www.dailypolitical.com/2017/01/14/alexion-pharmaceuticals-inc-alxn-director-sells-14499-00-in-stock.html.

ALXN has been the topic of several recent research reports. Vetr upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 target price on the stock in a report on Thursday, September 29th. Goldman Sachs Group, Inc. (The) upgraded Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $158.00 target price on the stock in a report on Friday, October 28th. RBC Capital Markets set a $188.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 12th. Wedbush restated a “neutral” rating and set a $135.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, December 13th. Finally, Leerink Swann restated an “outperform” rating on shares of Alexion Pharmaceuticals in a report on Friday, December 23rd. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $172.80.

A number of hedge funds have recently made changes to their positions in the company. Baker BROS. Advisors LP bought a new position in shares of Alexion Pharmaceuticals during the third quarter worth $801,815,000. FMR LLC raised its position in shares of Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares during the period. BlackRock Investment Management LLC raised its position in shares of Alexion Pharmaceuticals by 177.0% in the third quarter. BlackRock Investment Management LLC now owns 2,243,677 shares of the biopharmaceutical company’s stock worth $274,940,000 after buying an additional 1,433,769 shares during the period. BlackRock Advisors LLC raised its position in shares of Alexion Pharmaceuticals by 130.7% in the third quarter. BlackRock Advisors LLC now owns 2,286,891 shares of the biopharmaceutical company’s stock worth $280,236,000 after buying an additional 1,295,520 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of Alexion Pharmaceuticals by 34.8% in the second quarter. TIAA CREF Investment Management LLC now owns 2,952,205 shares of the biopharmaceutical company’s stock worth $344,699,000 after buying an additional 762,010 shares during the period. Hedge funds and other institutional investors own 94.79% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.